BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-16@pharmaconomics
DTSTAMP:20260707T030108Z
DTSTART;VALUE=DATE:20260505
DTEND;VALUE=DATE:20260506
SUMMARY:VRDN Phase 3 — elegrobart
DESCRIPTION:Phase 3 trial results for elegrobart in thyroid eye disease (TED) are due May 5\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1590750/000119312526205099/d20977dex991.htm\n\nTrack it: https://pharmaconomics.com/e/16
URL:https://pharmaconomics.com/e/16
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VRDN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR